Vanguard Capital Management
CDIO icon

Vanguard Capital Management’s Cardio Diagnostics CDIO Stock Holding History

Vanguard Capital Management’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.1K Hold
20,155
– – ﹤0.01% 3946
2026
Q1 		$39.3K Buy
+20,155
New +$52.7K ﹤0.01% 3943

Other funds holding CDIO

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management's CDIO Position: Q2 2026 in Review

Vanguard Capital Management held its Cardio Diagnostics (CDIO) position steady in Q2 2026 at 20,155 shares worth $44.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3946.

Vanguard Capital Management first reported a position in CDIO in Q1 2026 and has held it in 2 quarters since. 17 funds tracked by Wall St. Rank hold CDIO as of Q2 2026.

  • Vanguard Capital Management held 20,155 shares of Cardio Diagnostics worth $44.1K as of Q2 2026.
  • Vanguard Capital Management left its Cardio Diagnostics share count unchanged in Q2 2026.
  • Cardio Diagnostics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3946 holding.
  • Vanguard Capital Management first reported a position in Cardio Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • 17 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.